Menu Search
Equities

Medcamp SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MDP:WSE

Medcamp SA

Actions
Real EstateReal Estate Investment and Services
  • Price (PLN)0.80
  • Today's Change0.01 / 1.27%
  • Shares traded6.93k
  • 1 Year change+0.25%
  • Beta1.0795
Data delayed at least 15 minutes, as of Feb 27 2026.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medcamp SA, formerly T2 Investment SA, is a Poland-based company engaged in the real estate operations. The Company is involved in the acquisition, management, redevelopment and upgrade, as well as rental and sale of commercial properties, including office areas and warehouses. In addition, the Company is involved in long-term investments in construction and real estate entities. It conducts rental and redevelopment projects, such as Poznan, Jasielska; Poznan, Komorniki; Poznan, Jasielska, Inkubator; Szamotuly, Dworcowa; among others. The Company aims to build a research and development center in Poznan, specializing in such areas as personalized medicine, genetics, genomics and bioinformatics, supported by artificial intelligence, The Company operates through subsidiaries, including T2 Inkubator Sp z o o, T2 Szamotuly Sp z o o, Polskie Centrum Badan i Rozwoju Sp z o o, among others. The majority shareholder of the Company is Moonrock Enterprise SA.

  • Revenue in PLN (TTM)0.00
  • Net income in PLN-3.41m
  • Incorporated2007
  • Employees0.00
  • Location
    Medcamp SAul. Jeleniogorska 16 C/3POZNAN 60-179PolandPOL
  • Phone+48 616648000
  • Fax+48 616648029
  • Websitehttps://medcampsa.pl/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.